ArticleJMIR public health and surveillance2026
Effectiveness of Inactivated COVID-19 Vaccination Against COVID-19-Related Hospitalization and Severe Outcomes in Adults ≥80 Years During Omicron Circulation in Beijing, China: Retrospective Cohort Study.
Article in JMIR public health and surveillance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A large wave of COVID-19 caused by SARS-CoV-2 Omicron subvariants began in Beijing in early December 2022. Objective: This study aimed to evaluate the COVID-19 vaccine effectiveness (VE) in mitigating the risk of COVID-19-related hospitalization during the epidemic. Methods: We conducted a retrospective cohort study linking regional health care data and vaccination registry routinely collected in Beijing. All electronic medical records on COVID-19-related hospital discharges of older inpatients aged ≥80 years during November 2022 and February 2023 were included. Poisson regressions were used to estimate incidence risk ratio of COVID-19-related hospitalization, severe or critical cases, and in-hospital death compared with unvaccinated groups, adjusting for gender and age. VE was calculated as 1 minus incidence risk ratio×100%. Results: A total of 53,789 individuals aged ≥80 years were included, 28,423 (52.84%) were male, 45,270 (84.16%) were aged 80-89 years, and 8519 (15.84%) were aged ≥90 years. Overall, 30,531 (56.76%) were in the vaccine group, with 4524 (8.41%) of the total participants receiving partial vaccination, 20.91% completing the primary series, and 14,761 (27.44%) receiving one booster. Additionally, 23,258 (43.24%) were in the unvaccinated group. Of the 53,789 hospitalized individuals, 17,916 (33.31%) had a COVID-19 diagnosis, 3535 (6.57%) had COVID-19-related hospitalization, 961 (1.79%) were COVID-19 severe or critical cases, and 4130 (7.68%) had in-hospital death. The analysis revealed that the VE of booster vaccination in preventing COVID-19-related hospital, severe or critical COVID-19, and in-hospital death was 63.5% (95% CI 59.8%-66.9%), 66.9% (95% CI 60.1%-72.6%) and 79.4% (95% CI 77%-81.5%), the VE of primary series 56% (95% CI 51.4%-60.2%), 66.8% (95% CI 59%-73%) and 66.4% (95% CI 63%-69.5%). Conclusions: The first booster vaccination was associated with significantly reduced the risk of COVID-19-related severe outcomes in older inpatients aged ≥80 years during the Omicron-dominant period. Considering the potential selection bias and unmeasured confounders, these estimates may reflect both the VE and the better baseline health status of the vaccinated older individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.